JP2011517942A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011517942A5 JP2011517942A5 JP2011504007A JP2011504007A JP2011517942A5 JP 2011517942 A5 JP2011517942 A5 JP 2011517942A5 JP 2011504007 A JP2011504007 A JP 2011504007A JP 2011504007 A JP2011504007 A JP 2011504007A JP 2011517942 A5 JP2011517942 A5 JP 2011517942A5
- Authority
- JP
- Japan
- Prior art keywords
- fvii polypeptide
- gla
- swap fix
- modified fvii
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100023804 Coagulation factor VII Human genes 0.000 claims 92
- 108010023321 Factor VII Proteins 0.000 claims 92
- 229940012413 factor vii Drugs 0.000 claims 92
- 102000004196 processed proteins & peptides Human genes 0.000 claims 88
- 108090000765 processed proteins & peptides Proteins 0.000 claims 88
- 229920001184 polypeptide Polymers 0.000 claims 87
- 230000004048 modification Effects 0.000 claims 35
- 238000012986 modification Methods 0.000 claims 35
- 102220520852 Dynein light chain Tctex-type 3_S60A_mutation Human genes 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 150000001413 amino acids Chemical class 0.000 claims 17
- 102220604090 Homeobox protein SIX3_S52A_mutation Human genes 0.000 claims 16
- 102100022641 Coagulation factor IX Human genes 0.000 claims 12
- 108010076282 Factor IX Proteins 0.000 claims 11
- 229960004222 factor ix Drugs 0.000 claims 11
- 102220504523 Organic solute transporter subunit alpha_M19K_mutation Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102220412822 c.160C>T Human genes 0.000 claims 5
- 208000009292 Hemophilia A Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 102220024780 rs199473488 Human genes 0.000 claims 4
- 102220636170 Cystatin-A_I42A_mutation Human genes 0.000 claims 3
- 208000031220 Hemophilia Diseases 0.000 claims 3
- 102220507071 Mothers against decapentaplegic homolog 1_I42S_mutation Human genes 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000013595 glycosylation Effects 0.000 claims 3
- 238000006206 glycosylation reaction Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 102200058924 rs121909542 Human genes 0.000 claims 3
- 102220276595 rs1553131446 Human genes 0.000 claims 3
- 102220020898 rs1800062 Human genes 0.000 claims 3
- 102220491410 ADP-ribosylation factor-like protein 16_T37N_mutation Human genes 0.000 claims 2
- 102220516207 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial_K38T_mutation Human genes 0.000 claims 2
- 102220523133 Eukaryotic translation initiation factor 4E-binding protein 2_T37E_mutation Human genes 0.000 claims 2
- 108010014173 Factor X Proteins 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 102220603445 Homeobox protein SIX3_K32T_mutation Human genes 0.000 claims 2
- 108010047066 R 396 Proteins 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 102200159067 c.130T>A Human genes 0.000 claims 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 239000003805 procoagulant Substances 0.000 claims 2
- 102200153433 rs104894817 Human genes 0.000 claims 2
- 102220076035 rs147623032 Human genes 0.000 claims 2
- 102220242717 rs1553780837 Human genes 0.000 claims 2
- 102220279183 rs876660634 Human genes 0.000 claims 2
- 102220556665 Acetylcholinesterase_G97S_mutation Human genes 0.000 claims 1
- 102220635301 Adenylate kinase isoenzyme 6_I42R_mutation Human genes 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 102220496805 DNA dC->dU-editing enzyme APOBEC-3A_R28E_mutation Human genes 0.000 claims 1
- 102220597860 DNA endonuclease RBBP8_K62R_mutation Human genes 0.000 claims 1
- 102220536010 Dynamin-1-like protein_K38A_mutation Human genes 0.000 claims 1
- 108010062466 Enzyme Precursors Proteins 0.000 claims 1
- 102000010911 Enzyme Precursors Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 102220471770 Fructose-bisphosphate aldolase A_E82Q_mutation Human genes 0.000 claims 1
- 101150022345 GAS6 gene Proteins 0.000 claims 1
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims 1
- 102220594400 HLA class I histocompatibility antigen, C alpha chain_D33F_mutation Human genes 0.000 claims 1
- 102220594399 HLA class I histocompatibility antigen, C alpha chain_D33S_mutation Human genes 0.000 claims 1
- 102220570133 Histone PARylation factor 1_K32Q_mutation Human genes 0.000 claims 1
- 102220603448 Homeobox protein SIX3_A34R_mutation Human genes 0.000 claims 1
- 102220603449 Homeobox protein SIX3_A34S_mutation Human genes 0.000 claims 1
- 102220603453 Homeobox protein SIX3_A34W_mutation Human genes 0.000 claims 1
- 102220603436 Homeobox protein SIX3_K32A_mutation Human genes 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 102000004067 Osteocalcin Human genes 0.000 claims 1
- 108090000573 Osteocalcin Proteins 0.000 claims 1
- 102220540445 Ovarian cancer-related protein 1_Y44S_mutation Human genes 0.000 claims 1
- 102220469874 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN_A34D_mutation Human genes 0.000 claims 1
- 102220520254 Phospholipase A2 group XV_D46C_mutation Human genes 0.000 claims 1
- 102220547369 Protein APCDD1_L65S_mutation Human genes 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 102000017975 Protein C Human genes 0.000 claims 1
- 102220467432 Protein Jade-1_K38S_mutation Human genes 0.000 claims 1
- 229940096437 Protein S Drugs 0.000 claims 1
- 108010066124 Protein S Proteins 0.000 claims 1
- 102220626843 Protein phosphatase 1 regulatory subunit 35_S45D_mutation Human genes 0.000 claims 1
- 108010094028 Prothrombin Proteins 0.000 claims 1
- 102100027378 Prothrombin Human genes 0.000 claims 1
- 102220631868 Regulator of G-protein signaling 2_W41D_mutation Human genes 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- 102220494687 Small vasohibin-binding protein_R36E_mutation Human genes 0.000 claims 1
- 102220586119 Tubulin polymerization-promoting protein_S45E_mutation Human genes 0.000 claims 1
- 102100028885 Vitamin K-dependent protein S Human genes 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 102220414499 c.131A>G Human genes 0.000 claims 1
- 102200102393 c.194T>A Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 208000011664 congenital factor XI deficiency Diseases 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102220500037 eIF5-mimic protein 2_K32G_mutation Human genes 0.000 claims 1
- 201000007386 factor VII deficiency Diseases 0.000 claims 1
- 201000007219 factor XI deficiency Diseases 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 108010004351 growth arrest-specific protein 6 Proteins 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000043253 matrix Gla protein Human genes 0.000 claims 1
- 108010057546 matrix Gla protein Proteins 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 108010025221 plasma protein Z Proteins 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 229940039716 prothrombin Drugs 0.000 claims 1
- 102220033735 rs104886489 Human genes 0.000 claims 1
- 102200145342 rs104894410 Human genes 0.000 claims 1
- 102220234446 rs1064795967 Human genes 0.000 claims 1
- 102220004442 rs121918685 Human genes 0.000 claims 1
- 102220095974 rs149101834 Human genes 0.000 claims 1
- 102220253478 rs1553261891 Human genes 0.000 claims 1
- 102220249718 rs1553408194 Human genes 0.000 claims 1
- 102220321823 rs1554812271 Human genes 0.000 claims 1
- 102220288148 rs1554893773 Human genes 0.000 claims 1
- 102220071725 rs199473488 Human genes 0.000 claims 1
- 102220008235 rs199476326 Human genes 0.000 claims 1
- 102220249828 rs267606858 Human genes 0.000 claims 1
- 102220005499 rs33938574 Human genes 0.000 claims 1
- 102200067545 rs33985574 Human genes 0.000 claims 1
- 102200118254 rs33995148 Human genes 0.000 claims 1
- 102220005309 rs33995148 Human genes 0.000 claims 1
- 102200082816 rs34868397 Human genes 0.000 claims 1
- 102200066497 rs35629723 Human genes 0.000 claims 1
- 102220114727 rs372166877 Human genes 0.000 claims 1
- 102220297938 rs375722926 Human genes 0.000 claims 1
- 102220005421 rs41381645 Human genes 0.000 claims 1
- 102220037197 rs587780270 Human genes 0.000 claims 1
- 102200020878 rs73015965 Human genes 0.000 claims 1
- 102220323551 rs771587118 Human genes 0.000 claims 1
- 102220217756 rs777095030 Human genes 0.000 claims 1
- 102220272417 rs80357066 Human genes 0.000 claims 1
- 102200057185 rs863225150 Human genes 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12402108P | 2008-04-11 | 2008-04-11 | |
| US61/124,021 | 2008-04-11 | ||
| PCT/US2009/002248 WO2009126307A2 (en) | 2008-04-11 | 2009-04-10 | Factor vii polypeptides that are modified and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014002379A Division JP5976021B2 (ja) | 2008-04-11 | 2014-01-09 | 改変された第ｖｉｉ因子ポリペプチドおよびその使用 |
| JP2014155757A Division JP5659312B1 (ja) | 2008-04-11 | 2014-07-31 | 改変された第ｖｉｉ因子ポリペプチドおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011517942A JP2011517942A (ja) | 2011-06-23 |
| JP2011517942A5 true JP2011517942A5 (enExample) | 2012-06-07 |
Family
ID=40872757
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011504007A Pending JP2011517942A (ja) | 2008-04-11 | 2009-04-10 | 改変された第ｖｉｉ因子ポリペプチドおよびその使用 |
| JP2014002379A Expired - Fee Related JP5976021B2 (ja) | 2008-04-11 | 2014-01-09 | 改変された第ｖｉｉ因子ポリペプチドおよびその使用 |
| JP2014155757A Expired - Fee Related JP5659312B1 (ja) | 2008-04-11 | 2014-07-31 | 改変された第ｖｉｉ因子ポリペプチドおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014002379A Expired - Fee Related JP5976021B2 (ja) | 2008-04-11 | 2014-01-09 | 改変された第ｖｉｉ因子ポリペプチドおよびその使用 |
| JP2014155757A Expired - Fee Related JP5659312B1 (ja) | 2008-04-11 | 2014-07-31 | 改変された第ｖｉｉ因子ポリペプチドおよびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US8519103B2 (enExample) |
| EP (4) | EP3064580A1 (enExample) |
| JP (3) | JP2011517942A (enExample) |
| KR (1) | KR101623602B1 (enExample) |
| CN (2) | CN105039291A (enExample) |
| AU (1) | AU2009234390B2 (enExample) |
| BR (1) | BRPI0911060B1 (enExample) |
| CA (1) | CA2721038C (enExample) |
| CO (1) | CO6331368A2 (enExample) |
| DK (2) | DK2687596T3 (enExample) |
| EA (2) | EA024760B1 (enExample) |
| ES (3) | ES2577055T3 (enExample) |
| HU (1) | HUE026937T2 (enExample) |
| IL (2) | IL208373A (enExample) |
| MX (2) | MX344220B (enExample) |
| MY (1) | MY161581A (enExample) |
| NZ (1) | NZ588322A (enExample) |
| PL (1) | PL2281037T3 (enExample) |
| PT (1) | PT2281037E (enExample) |
| SG (2) | SG193779A1 (enExample) |
| SI (1) | SI2281037T1 (enExample) |
| TW (2) | TWI538916B (enExample) |
| WO (1) | WO2009126307A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700341B2 (en) * | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| DK1735439T3 (da) | 2004-04-12 | 2012-02-06 | Catalyst Biosciences Inc | Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1 |
| US20090055942A1 (en) | 2005-09-14 | 2009-02-26 | Novo Nordisk Healthcare A/G | Human Coagulation Factor VII Polypeptides |
| AU2006304804B2 (en) * | 2005-10-21 | 2011-06-02 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
| EP2423305A1 (en) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
| EP2402437B1 (en) | 2006-07-05 | 2016-06-01 | Catalyst Biosciences, Inc. | Protease screening methods and proteases identified thereby |
| NZ579985A (en) * | 2007-04-13 | 2012-02-24 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| US8647620B2 (en) | 2009-06-25 | 2014-02-11 | The University Of North Carolina At Chapel Hill | Chimeric factor VII molecules |
| DK2591006T3 (da) | 2010-07-09 | 2019-07-29 | Bioverativ Therapeutics Inc | Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf |
| EP2625264B1 (en) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| WO2012142317A1 (en) * | 2011-04-15 | 2012-10-18 | Gamma Therapeutics, Inc | Fast-clotting wound dressings |
| WO2012149463A1 (en) * | 2011-04-29 | 2012-11-01 | The University Of North Carolina At Chapel Hill | Chimeric factor vii molecules with enhanced half life and methods of use |
| HUE043894T2 (hu) | 2011-06-10 | 2019-09-30 | Bioverativ Therapeutics Inc | Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei |
| EP2554161A1 (en) | 2011-08-02 | 2013-02-06 | LFB Biotechnologies | Pharmaceutical composition comprising factor VII encapsulated in micelles |
| EA028578B1 (ru) * | 2012-02-14 | 2017-12-29 | Опко Байолоджикс Лтд. | Факторы свертывания крови пролонгированного действия и способы их получения |
| AP2014008049A0 (en) | 2012-04-16 | 2014-11-30 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcuraneous therapeutic agents |
| BR112015001628A2 (pt) | 2012-07-25 | 2017-11-07 | Catalyst Biosciences Inc | polipeptídeos de fator x modificados e uso dos mesmos |
| JP2015532307A (ja) | 2012-10-15 | 2015-11-09 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 凝固因子ｖｉｉポリペプチド |
| CN104661685A (zh) | 2012-10-15 | 2015-05-27 | 诺和诺德保健Ag（股份有限公司） | 因子vii缀合物 |
| PL2938351T3 (pl) | 2012-12-24 | 2020-03-31 | Coagulant Therapeutics Corporation | Krótko działające polipeptydy czynnika VII |
| UY35463A (es) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix. |
| CN103397009B (zh) * | 2013-08-16 | 2015-06-03 | 安源生物科技(上海)有限公司 | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 |
| MX2016004702A (es) * | 2013-10-15 | 2016-07-22 | Novo Nordisk Healthcare Ag | Polipeptidos del factor vii de coagulacion. |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| EP3068866B1 (en) | 2013-11-16 | 2018-04-25 | Terumo BCT, Inc. | Expanding cells in a bioreactor |
| AR099328A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados de factor vii |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| NZ727444A (en) | 2014-05-26 | 2021-12-24 | Academisch Ziekenhuis Leiden | Prohemostatic proteins for the treatment of bleeding |
| US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
| CA2972800A1 (en) | 2015-01-02 | 2016-07-07 | Dyax Corp. | Bispecific antibodies against plasma kallikrein and factor xii |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US10913802B2 (en) | 2015-07-21 | 2021-02-09 | Dyax Corp. | Monoclonal antibody inhibitor of factor XIIA |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| EP3442554A4 (en) * | 2016-04-14 | 2019-12-04 | Iconic Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION |
| WO2017205667A1 (en) | 2016-05-25 | 2017-11-30 | Terumo Bct, Inc. | Cell expansion |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| WO2018005716A2 (en) * | 2016-07-01 | 2018-01-04 | Denali Therapeutics Inc. | Albumin variants for enhanced serum half-life |
| US20210284715A1 (en) * | 2017-02-06 | 2021-09-16 | Applied Stemcell, Inc. | Coagulation factor viii mimetic protein and uses thereof |
| CN110612344B (zh) | 2017-03-31 | 2023-09-12 | 泰尔茂比司特公司 | 细胞扩增 |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| US11981723B2 (en) * | 2017-09-05 | 2024-05-14 | GLAdiator Biosciences, Inc. | Method of targeting exosomes |
| CA3077380A1 (en) | 2017-09-27 | 2019-04-04 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising active cells |
| WO2019071028A1 (en) | 2017-10-04 | 2019-04-11 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
| MA51583A (fr) * | 2018-01-04 | 2020-11-11 | Avidity Biosciences Inc | Molécules d'acide nucléique hétéroduplex et leurs utilisations |
| UY38160A (es) | 2018-04-04 | 2019-11-29 | Sigilon Therapeutics Inc | Partículas implantables y métodos relacionados |
| US20210145889A1 (en) | 2018-04-04 | 2021-05-20 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| WO2020010189A1 (en) * | 2018-07-06 | 2020-01-09 | Children's Medical Center Corporation | Methods and compositions for analyzing platelets by mass cytometry |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| JP7581252B2 (ja) | 2019-06-06 | 2024-11-12 | アビディティー バイオサイエンシーズ，インク． | Ｕｎａアミダイトおよびその使用 |
| US11578090B2 (en) | 2019-06-06 | 2023-02-14 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
| WO2021136194A1 (zh) * | 2019-12-30 | 2021-07-08 | 南京金斯瑞生物科技有限公司 | 构建基因突变文库的方法 |
| JP7759719B2 (ja) * | 2020-02-27 | 2025-10-24 | オムロン株式会社 | 流量測定装置 |
| WO2022204315A1 (en) | 2021-03-23 | 2022-09-29 | Terumo Bct, Inc. | Cell capture and expansion |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| EP4602154A1 (en) | 2022-10-11 | 2025-08-20 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
| WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
| US12385818B2 (en) | 2023-02-14 | 2025-08-12 | Saudi Arabian Oil Company | Modeling gas desorption in a subsurface reservoir |
| CN118126161B (zh) * | 2024-03-26 | 2025-10-24 | 福州大学 | 一种凝血因子FXIa的多肽抑制剂及其在抗凝治疗方面的应用 |
| CN119372186B (zh) * | 2024-12-30 | 2025-04-15 | 深圳市卫光生物制品股份有限公司 | 一种重组人凝血因子vii的纯化方法和应用 |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) * | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5033252A (en) * | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033352A (en) | 1989-01-19 | 1991-07-23 | Yamaha Corporation | Electronic musical instrument with frequency modulation |
| US5304482A (en) | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| JP3330932B2 (ja) * | 1990-01-29 | 2002-10-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 抗凝固剤タンパク質 |
| US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US20040087498A1 (en) * | 1991-02-28 | 2004-05-06 | Novo Nordisk Health Care Ag | Modified factor VII |
| US5997864A (en) * | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
| US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| ATE455552T1 (de) * | 1997-02-14 | 2010-02-15 | American Nat Red Cross | Expression des active human factor ix im brustdrüsengewebe transgener tiere |
| US20050032690A1 (en) | 1997-09-10 | 2005-02-10 | Rojkjaer Lisa Payne | Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
| US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6017882A (en) * | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| DE19937219A1 (de) * | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie |
| AU1436401A (en) | 1999-10-21 | 2001-05-14 | Board Of Trustees Of The University Of Arkansas, The | RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US6797504B1 (en) | 2000-09-08 | 2004-09-28 | Dendreon San Diego Llc | Inhibitors of serine protease activity of matriptase or MTSP1 |
| US7700341B2 (en) * | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| DE60138364D1 (de) * | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6905683B2 (en) * | 2000-05-03 | 2005-06-14 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
| AU2001254624A1 (en) | 2000-05-03 | 2001-11-12 | Novo-Nordisk A/S | Human coagulation factor vii variants |
| EP1280548B1 (en) | 2000-05-03 | 2013-12-11 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor VII |
| ES2254414T3 (es) | 2000-05-10 | 2006-06-16 | Novo Nordisk Health Care Ag | Composicion farmaceutica comprendiendo un factor vlla y un inhibidor tfpi. |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US7176288B2 (en) * | 2000-09-13 | 2007-02-13 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
| EP1319067A2 (en) | 2000-09-13 | 2003-06-18 | Novo Nordisk A/S | Human coagulation factor vii variants |
| KR100880624B1 (ko) | 2000-10-02 | 2009-01-30 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 비타민 ｋ-의존 단백질의 생산 방법 |
| AU2002218029A1 (en) * | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
| WO2002062377A2 (en) | 2001-02-05 | 2002-08-15 | Novo Nordisk Health Care Ag | Combined use of factor vii polypeptides and factor viii polypeptides |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| US20040133930A1 (en) * | 2002-03-11 | 2004-07-08 | Cooper Julian D. | Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses |
| WO2002072786A2 (en) | 2001-03-13 | 2002-09-19 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
| PL371800A1 (en) | 2001-03-22 | 2005-06-27 | Novo Nordisk Health Care Ag | Coagulation factor vii derivatives |
| JP2004535166A (ja) | 2001-03-22 | 2004-11-25 | デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー | セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法 |
| US7235638B2 (en) * | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
| KR20030096292A (ko) | 2001-03-27 | 2003-12-24 | 덴드레온 샌 디에고 엘엘씨 | 트랜스막 세린 프로테아제 9를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법 |
| US7112430B2 (en) | 2001-05-14 | 2006-09-26 | Dendreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| EP1545572A4 (en) | 2001-05-23 | 2006-04-12 | Dendreon Corp | CELL SURFACE PROTEINS ACTIVATED CONJUGATES AND THERAPEUTIC USES THEREOF |
| AU2002315525A1 (en) * | 2001-07-03 | 2003-01-21 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon |
| US7419949B2 (en) * | 2001-07-16 | 2008-09-02 | Novo Noridsk Healthcare A/G | Single-dose administration of factor VIIa |
| UA82177C2 (uk) | 2001-09-27 | 2008-03-25 | Ново Нордиск Хэлс Кеа Аг | Поліпептиди фактора коагуляції vii людини |
| US7052868B2 (en) * | 2001-09-27 | 2006-05-30 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| EP1434857B1 (en) | 2001-10-02 | 2007-08-01 | Novo Nordisk Health Care AG | Method for production of recombinant proteins in eukaryote cells |
| US20030143219A1 (en) * | 2001-10-09 | 2003-07-31 | Madison Edwin L | Nucleic acid molecules encoding a transmembrane serine protease 25, the encoded polypeptides and methods based thereon |
| JP3862996B2 (ja) | 2001-10-31 | 2006-12-27 | 帝人ファイバー株式会社 | ポリトリメチレンテレフタレートフィラメント糸およびその製造方法 |
| US6960657B2 (en) * | 2001-11-02 | 2005-11-01 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| EP1451315B1 (en) | 2001-11-02 | 2014-05-21 | Novo Nordisk Health Care AG | Human coagulation factor vii polypeptides |
| US7291587B2 (en) * | 2001-11-09 | 2007-11-06 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides |
| AU2002357004A1 (en) * | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
| AU2002351756A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
| AU2002351755A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk A/S | Liquid composition of modified factor vii polypeptides |
| CN101942019A (zh) * | 2002-04-30 | 2011-01-12 | 拜耳医药保健有限公司 | 凝血因子VII或VIIa多肽变体 |
| EP1361284A1 (en) | 2002-05-10 | 2003-11-12 | Direvo Biotech AG | Process for generating sequence-specific proteases by directed evolution and use thereof |
| AU2003269880A1 (en) | 2002-05-21 | 2003-12-22 | Dendreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon |
| US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| WO2003106493A1 (en) | 2002-06-14 | 2003-12-24 | Dyax Corporation | Protein analysis |
| DE60336555D1 (de) | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
| KR101186140B1 (ko) | 2002-06-21 | 2012-09-27 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 페길화된 인자 ｖｉｉ 글리코형태 |
| WO2004005471A2 (en) | 2002-07-02 | 2004-01-15 | Dendreon Corporation | Serine protease 16 |
| US6911323B2 (en) * | 2002-09-25 | 2005-06-28 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| EP1908782B1 (en) | 2002-09-25 | 2010-01-06 | Novo Nordisk Health Care AG | Human coagulation factor VII polypeptides |
| AU2003266931B2 (en) * | 2002-09-30 | 2010-01-21 | Bayer Healthcare Llc | FVII or FVIIa variants having increased clotting activity |
| US20060024289A1 (en) * | 2002-10-02 | 2006-02-02 | Ruggles Sandra W | Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases |
| US7939304B2 (en) * | 2002-10-02 | 2011-05-10 | Catalyst Biosciences, Inc. | Mutant MT-SP1 proteases with altered substrate specificity or activity |
| ZA200502867B (en) | 2002-10-02 | 2007-09-26 | Catalyst Biosciences Inc | Methods of generating and screening for proteases with altered specificity |
| EP1611236A1 (en) | 2003-03-18 | 2006-01-04 | Novo Nordisk Health Care AG | Method for the production of gla-residue containing serine proteases |
| JP4847856B2 (ja) | 2003-03-20 | 2011-12-28 | バイエル ヘルスケア エルエルシー | ＦＶＩＩおよびＦＶＩＩａの変種 |
| WO2004108763A2 (en) | 2003-06-05 | 2004-12-16 | Canadian Blood Services | Mutants of the factor vii epidermal growth factor domain |
| WO2004110469A2 (en) | 2003-06-13 | 2004-12-23 | Novo Nordisk Health Care Ag | Formulations comprising factor viia and a factor vii related polypeptide |
| US20060116324A1 (en) * | 2003-06-13 | 2006-06-01 | Novo Nordisk Healthcare A/G | Novel formulations |
| AU2004249904A1 (en) | 2003-06-18 | 2004-12-29 | Direvo Biotech Ag | New biological entities and the pharmaceutical or diagnostic use thereof |
| AU2004249903B2 (en) | 2003-06-18 | 2009-06-04 | Bayer Schering Pharma Aktiengesellschaft | New biological entities and the use thereof |
| EP1644504B8 (en) | 2003-06-19 | 2010-06-02 | Bayer HealthCare LLC | Factor vii or viia gla domain variants |
| WO2005023308A1 (en) | 2003-09-05 | 2005-03-17 | Maxygen Holdings Ltd. | Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins |
| CN1863908B (zh) * | 2003-09-09 | 2010-08-04 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
| EP1664291B1 (en) | 2003-09-09 | 2012-02-29 | Novo Nordisk Health Care AG | Coagulation factor vii polypeptides |
| WO2005032581A2 (en) * | 2003-10-07 | 2005-04-14 | Novo Nordisk Health Care Ag | Hybrid molecules having factor vii/viia activity |
| JP2007511604A (ja) | 2003-11-18 | 2007-05-10 | アイコニック セラピューティクス インコーポレイティッド | キメラタンパク質の均質製剤 |
| WO2005068620A1 (en) | 2004-01-07 | 2005-07-28 | Novo Nordisk Health Care Ag | Method for the production of recombinant proteins |
| EP1713906A2 (en) | 2004-02-03 | 2006-10-25 | Novo Nordisk Health Care AG | Coagulation factor vii/viia variants lacking functional lipid membrane binding domain |
| DK1735439T3 (da) * | 2004-04-12 | 2012-02-06 | Catalyst Biosciences Inc | Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1 |
| WO2005100556A2 (en) | 2004-04-12 | 2005-10-27 | Catalyst Biosciences | Cleavage of vegf and vegf receptor by wild-type and mutant proteases |
| EP1745141B2 (en) | 2004-05-04 | 2019-09-25 | Novo Nordisk Health Care AG | O-linked glycoforms of faktor vii and method to manufacture them |
| US20060029590A1 (en) * | 2004-06-10 | 2006-02-09 | Christopher Thanos | Administration of neutral endopeptidase to treat inflammatory bowel disease |
| WO2005123916A2 (en) | 2004-06-21 | 2005-12-29 | Novo Nordisk Health Care Ag | Glycosylation-disrupted factor vii variants |
| BRPI0512316A (pt) | 2004-06-21 | 2008-02-26 | Novo Nordisk Healthcare Ag | métodos para prevenir ou atenuar uma ou mais complicações da hemorragia intracerebral e para prevenir ou atenuar uma ou mais complicações da ich em uma maioria de pacientes com ich, e, uso de um primeiro agente de coagulação |
| US20060019893A1 (en) * | 2004-07-02 | 2006-01-26 | Genentech, Inc. | Factor VIIa variants |
| WO2006008267A2 (en) | 2004-07-16 | 2006-01-26 | Novo Nordisk Health Care Ag | Methods for optimizing forming viiia-based hemostatic treatment |
| JP2008507990A (ja) | 2004-08-02 | 2008-03-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｆｖｉｉの抱合体 |
| EP1781782B1 (en) | 2004-08-17 | 2010-05-26 | CSL Behring GmbH | Modified vitamin k dependent polypeptides |
| JP2008514215A (ja) | 2004-09-29 | 2008-05-08 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 改変タンパク質 |
| EP1827486A2 (en) | 2004-12-22 | 2007-09-05 | Direvo Biotech AG | Targeted use of engineered enzymes |
| AU2005318106B2 (en) | 2004-12-23 | 2011-11-03 | Novo Nordisk Health Care Ag | Reduction of the content of protein contaminants in compositions comprising a Vitamin K-dependent protein of interest |
| EP1893230A2 (en) | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| US8703706B2 (en) | 2005-04-28 | 2014-04-22 | Novo Nordisk Healthcare Ag | Closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit |
| EP1726643A1 (en) | 2005-05-27 | 2006-11-29 | Direvo Biotech AG | Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| US20090041744A1 (en) | 2005-06-17 | 2009-02-12 | Novo Nordisk Healthcare A/G | Dimeric and Multimeric FVIIa Compounds |
| AU2006280932A1 (en) * | 2005-08-19 | 2007-02-22 | Novo Nordisk A/S | Glycopegylated factor VII and factor Vila |
| WO2007022784A2 (en) | 2005-08-26 | 2007-03-01 | Maxygen Holdings Ltd. | Liquid factor vii composition |
| EP1924688A1 (en) | 2005-09-01 | 2008-05-28 | Novo Nordisk Health Care AG | Purification of coagulation factor vii polypeptides |
| US20090055942A1 (en) * | 2005-09-14 | 2009-02-26 | Novo Nordisk Healthcare A/G | Human Coagulation Factor VII Polypeptides |
| EP1929005A1 (en) | 2005-09-21 | 2008-06-11 | Novo Nordisk Health Care AG | Human coagulation factor vii polypeptides |
| US20090221484A1 (en) | 2005-10-07 | 2009-09-03 | Novo Nordisk A/S | Use of Factor VII Polypeptides for Neuroprotection |
| AU2006304804B2 (en) | 2005-10-21 | 2011-06-02 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
| EP2423305A1 (en) | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
| EP2402437B1 (en) | 2006-07-05 | 2016-06-01 | Catalyst Biosciences, Inc. | Protease screening methods and proteases identified thereby |
| WO2008009635A2 (en) | 2006-07-17 | 2008-01-24 | Novo Nordisk Health Care Ag | Factor viia analogues with increased activity for treating thrombocytopenia |
| CA2673260A1 (en) | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | Factor vii and viia compositions |
| EP1952822A1 (en) * | 2007-01-26 | 2008-08-06 | Novo Nordisk A/S | Factor VII polypeptides with increased affinity to platelets |
| NZ579985A (en) | 2007-04-13 | 2012-02-24 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| US9102962B2 (en) | 2007-10-16 | 2015-08-11 | Shiu Nan Chen | Production method for solid cultured active mushroom mycelium and fruit-body metabolites (AMFM) products thereof |
| GB0800938D0 (en) * | 2008-01-18 | 2008-02-27 | Ge Healthcare Uk Ltd | Multiplex cell signalling assay |
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| US8266208B2 (en) | 2008-11-06 | 2012-09-11 | Joseph Mahon | Method and system for sharing documents among members of an online community |
| US8647620B2 (en) * | 2009-06-25 | 2014-02-11 | The University Of North Carolina At Chapel Hill | Chimeric factor VII molecules |
| CN201753815U (zh) | 2010-07-27 | 2011-03-02 | 江森自控空调冷冻设备(无锡)有限公司 | 三通结构 |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| BR112015001628A2 (pt) | 2012-07-25 | 2017-11-07 | Catalyst Biosciences Inc | polipeptídeos de fator x modificados e uso dos mesmos |
| JP2015532307A (ja) | 2012-10-15 | 2015-11-09 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 凝固因子ｖｉｉポリペプチド |
| US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
-
2009
- 2009-04-09 TW TW103116777A patent/TWI538916B/zh not_active IP Right Cessation
- 2009-04-09 TW TW098111791A patent/TWI465247B/zh not_active IP Right Cessation
- 2009-04-10 EA EA201301350A patent/EA024760B1/ru not_active IP Right Cessation
- 2009-04-10 EP EP16159675.4A patent/EP3064580A1/en not_active Withdrawn
- 2009-04-10 PT PT97308522T patent/PT2281037E/pt unknown
- 2009-04-10 AU AU2009234390A patent/AU2009234390B2/en not_active Ceased
- 2009-04-10 CN CN201510387292.3A patent/CN105039291A/zh active Pending
- 2009-04-10 MX MX2012012083A patent/MX344220B/es unknown
- 2009-04-10 ES ES13162174.0T patent/ES2577055T3/es active Active
- 2009-04-10 PL PL09730852T patent/PL2281037T3/pl unknown
- 2009-04-10 EA EA201001628A patent/EA020818B1/ru not_active IP Right Cessation
- 2009-04-10 KR KR1020107025264A patent/KR101623602B1/ko active Active
- 2009-04-10 MX MX2010011170A patent/MX2010011170A/es active IP Right Grant
- 2009-04-10 MY MYPI2010004758A patent/MY161581A/en unknown
- 2009-04-10 EP EP13162174.0A patent/EP2679678B1/en active Active
- 2009-04-10 DK DK13162166.6T patent/DK2687596T3/da active
- 2009-04-10 SG SG2013057724A patent/SG193779A1/en unknown
- 2009-04-10 DK DK09730852.2T patent/DK2281037T3/en active
- 2009-04-10 EP EP09730852.2A patent/EP2281037B1/en active Active
- 2009-04-10 SI SI200931368T patent/SI2281037T1/sl unknown
- 2009-04-10 WO PCT/US2009/002248 patent/WO2009126307A2/en not_active Ceased
- 2009-04-10 ES ES13162166.6T patent/ES2560236T3/es active Active
- 2009-04-10 CA CA2721038A patent/CA2721038C/en active Active
- 2009-04-10 EP EP13162166.6A patent/EP2687596B1/en active Active
- 2009-04-10 HU HUE09730852A patent/HUE026937T2/en unknown
- 2009-04-10 CN CN200980121895.1A patent/CN102083971B/zh active Active
- 2009-04-10 SG SG2013027644A patent/SG190560A1/en unknown
- 2009-04-10 JP JP2011504007A patent/JP2011517942A/ja active Pending
- 2009-04-10 ES ES09730852.2T patent/ES2556596T3/es active Active
- 2009-04-10 BR BRPI0911060-7A patent/BRPI0911060B1/pt not_active IP Right Cessation
- 2009-04-10 US US12/384,915 patent/US8519103B2/en active Active
- 2009-04-10 NZ NZ588322A patent/NZ588322A/en unknown
-
2010
- 2010-10-03 IL IL208373A patent/IL208373A/en active IP Right Grant
- 2010-10-13 CO CO10127271A patent/CO6331368A2/es not_active Application Discontinuation
-
2013
- 2013-04-14 IL IL225740A patent/IL225740A/en active IP Right Grant
- 2013-07-30 US US13/987,492 patent/US9476037B2/en active Active
-
2014
- 2014-01-09 JP JP2014002379A patent/JP5976021B2/ja not_active Expired - Fee Related
- 2014-07-31 JP JP2014155757A patent/JP5659312B1/ja not_active Expired - Fee Related
-
2016
- 2016-09-07 US US15/258,908 patent/US10160961B2/en active Active
-
2018
- 2018-11-02 US US16/179,642 patent/US11203749B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011517942A5 (enExample) | ||
| JP2014113157A5 (enExample) | ||
| ES2556596T3 (es) | Polipéptidos de factor VII que se modifican y usos de los mismos | |
| ES2574581T3 (es) | Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII | |
| US20220064605A1 (en) | Virus Filtration of Liquid Factor VII Compositions | |
| JP2012095641A5 (enExample) | ||
| JP2013151494A (ja) | 活性化型のｖｉｉ因子ポリペプチドを含んでいる閉鎖容器、調製する方法、並びにキットおよび前記キットを使用する方法 | |
| JP5836910B2 (ja) | 陰イオン交換物質からの分画溶出によるｖｉｉ因子ポリペプチドのバルクの精製 | |
| CN102065899A (zh) | 含有高浓度的芳香族防腐剂的peg-官能化的丝氨酸蛋白酶的制剂 | |
| US20090191180A1 (en) | Use of Factor VIIa Analogues with Increased Activity | |
| CN104887620A (zh) | 包括芳香族防腐剂和抗氧化剂的高浓度因子vii多肽制剂 | |
| WO2004110469A2 (en) | Formulations comprising factor viia and a factor vii related polypeptide | |
| WO2004056384A2 (en) | Use of factor vii polypeptides for preventing formation of inhibitors to blood coagulation factor viii and ix | |
| WO2009027478A2 (en) | A method of removing preservatives from a liquid pharmaceutical preparation | |
| JP2007537205A (ja) | 熱傷外傷の治療のためのＶＩＩａ因子の使用 | |
| AU2012213951B2 (en) | A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit | |
| JP5577249B2 (ja) | 加熱処理による第ｖｉｉ因子ポリペプチド組成物中の二量体含有量の低減 | |
| EP1989304B1 (en) | A method of removing a non-metallic protein inhibitor from a liquid pharmaceutical preparation | |
| AU2012201036B2 (en) | Virus filtration of liquid factor VII compositions | |
| CN101031586A (zh) | 通过去除desGla－因子Ⅶ多肽结构物来纯化因子Ⅶ多肽药品 | |
| MXPA06005967A (en) | Nanofiltration of factor vii solutions to remove virus |